FDA Alignment on Axpaxli and New CFO Might Change The Case For Investing In Ocular Therapeutix (OCUL)

Simply Wall St.06-22

Ocular Therapeutix has confirmed that interim Chief Financial Officer Jason Robins has been appointed as permanent CFO and that it reached alignment with the US FDA to submit a New Drug Application ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645076949?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-06-22 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645076949","market":"nz","top_or_hot":-1,"title":"FDA Alignment on Axpaxli and New CFO Might Change The Case For Investing In Ocular Therapeutix (OCUL)","media":"Simply Wall St.","content":"<div>\n<p>Ocular Therapeutix has confirmed that interim Chief Financial Officer Jason Robins has been appointed as permanent CFO and that it reached alignment with the US FDA to submit a New Drug Application ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/fda-alignment-on-axpaxli-and-new-cfo-might-change-the-case-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Alignment on Axpaxli and New CFO Might Change The Case For Investing In Ocular Therapeutix (OCUL)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Alignment on Axpaxli and New CFO Might Change The Case For Investing In Ocular Therapeutix (OCUL)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-22 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/fda-alignment-on-axpaxli-and-new-cfo-might-change-the-case-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocular Therapeutix has confirmed that interim Chief Financial Officer Jason Robins has been appointed as permanent CFO and that it reached alignment with the US FDA to submit a New Drug Application ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/fda-alignment-on-axpaxli-and-new-cfo-might-change-the-case-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARTY","symbol_name":"ISHARES FUTURE AI & TECH ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/fda-alignment-on-axpaxli-and-new-cfo-might-change-the-case-f","article_id":"2645076949","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/fda-alignment-on-axpaxli-and-new-cfo-might-change-the-case-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645076949","pubTimestamp":1782138059,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ocular Therapeutix has confirmed that interim Chief Financial Officer Jason Robins has been appointed as permanent CFO and that it reached alignment with the US FDA to submit a New Drug Application for its Axpaxli injection for wet age-related macular degeneration, which it plans to file in the fourth quarter of 2026.\nThis combination of regulatory clarity for Axpaxli and continuity in financial leadership further defines how Ocular Therapeutix is organizing around its lead retinal asset and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARTY":"ISHARES FUTURE AI & TECH ETF","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","LABU":"三倍做多标普生物-Direxion","BK4007":"制药","OCUL":"Ocular Therapeutix","BK4588":"碎股","BK4585":"ETF&股票定投概念","AGIX":"通用人工智能 ETF-AGIX","AIPO":"Defiance AI and Power Infrastructure ETF"},"translate_title":"FDA对Axpaxli和新任首席财务官的一致可能会改变投资眼部治疗(OCUL)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":0.72,"OCUL":1.5,"ARTY":0.62,"AGIX":0.62,"CHAT":0.62,"LABU":1.5},"content_text":"Ocular Therapeutix has confirmed that interim Chief Financial Officer Jason Robins has been appointed as permanent CFO and that it reached alignment with the US FDA to submit a New Drug Application for its Axpaxli injection for wet age-related macular degeneration, which it plans to file in the fourth quarter of 2026. This combination of regulatory clarity for Axpaxli and continuity in financial leadership further defines how Ocular Therapeutix is organizing around its lead retinal asset and longer-term development plans. Next, we will examine how FDA alignment on Axpaxli’s NDA submission timeline could influence Ocular Therapeutix’s investment narrative and risk profile. Uncover the next big thing with 24 elite penny stocks that balance risk and reward.AdvertisementOcular Therapeutix Investment Narrative RecapTo own Ocular Therapeutix today, you largely need to believe that AXPAXLI can successfully transition from late stage development into a commercial product while the company manages heavy losses and dilution risk. FDA agreement on a Q4 2026 NDA filing gives more visibility around the main near term catalyst, but the biggest risk remains any clinical or regulatory setback for AXPAXLI, given how dependent the business is on this single retinal program. The most relevant recent announcement here is the FDA alignment that allows Ocular to base its AXPAXLI NDA on SOL 1 data, with SOL R contributing interim results later. This clarification ties the regulatory timeline directly to existing trial data, sharpening focus on upcoming readouts as key inflection points for sentiment on both the product profile and the company’s ability to support its high cash burn. Yet against that clearer NDA path, investors still need to weigh the possibility that ongoing losses and dilution could... Read the full narrative on Ocular Therapeutix (it's free!)Ocular Therapeutix's narrative projects $335.8 million revenue and $65.7 million earnings by 2029. This requires 86.2% yearly revenue growth and an earnings increase of about $356 million from -$290.5 million today.Uncover how Ocular Therapeutix's forecasts yield a $26.00 fair value, a 176% upside to its current price.Exploring Other PerspectivesOCUL 1-Year Stock Price Chart Some of the most optimistic analysts were already assuming revenue could reach about US$252,000,000 by 2028, which is far more bullish than consensus and could look either more realistic or more stretched once the FDA aligned AXPAXLI timeline and the dilution and pipeline concentration risks are reassessed.Explore 5 other fair value estimates on Ocular Therapeutix - why the stock might be worth over 9x more than the current price!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.Searching For A Fresh Perspective?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Find 45 companies with promising cash flow potential yet trading below their fair value.The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645076949","isCrawlerRequest":true}